{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34","upperLimit":"70","value":"48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Percent Overall Survival (OS) for at one year for subjects with Acute Myeloid Leukemia (AML).","dispersionType":"95% Confidence Interval","groups":[{"description":"Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.\n\nAfter pre-conditioning, subjects will receive a peripheral blood stem cell transplant.\n\nTotal Lymphoid Irradiation : Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant\n\nClofarabine/Busulfan x 4 : Clofarabine IV (dose levels)\n\n* 1st dose level: 20 mg/m2/day x 5 days\n* 2nd dose level: 30 mg/m2/day x 5 days\n* 3rd dose level: 40 mg/m2/day x 5 days\n\nBusulfan IV 3.2 mg/kg daily x 4 days\n\nPeripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment","id":"OG000","title":"Clo/BU4"}],"paramType":"NUMBER","populationDescription":"Patients with Acute Myeloid Leukemia (AML)","reportingStatus":"POSTED","timeFrame":"1 year","title":"One-year Overall Survival Rate for AML","type":"PRIMARY","unitOfMeasure":"percent overall survival"}